Podcast appearances and mentions of Aaron S Kesselheim

The United States needs to tackle a big issue surrounding the soaring price of prescription medicine. In this episode, Aaron Kesselheim talks about the high cost of prescription medicine in the United States and the various factors contributing to this issue. He discusses the financial struggles of Americans due to increased medicine costs, delves into the reasons behind these prices, and explores recent legislative changes to address the issue. Tune in to learn how the US can unravel the puzzle of high prescription medicine costs! Learn more about the Institute of Healthcare Improvement on its website. Learn more about your ad choices. Visit megaphone.fm/adchoices

JAMA Health Forum Editor John Ayanian, MD, MPP, and Associate Editor Julie Donohue, PhD, speak with Aaron S. Kesselheim, MD, JD, MPH, and Genevieve P. Kanter, PhD, about the role of advisory committees convened by the US Food and Drug Administration (FDA) to guide its decisions on whether to approve new prescription drugs. They also consider how the FDA has responded to recommendations from these advisory committees over the past decade. Related Content: Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021 The Real Question the FDA Is Asking Its Advisory Committees

President Biden has signed into law the Inflation Reduction Act containing important provisions related to prescription drug costs. JAMA Health Forum Editor John Z. Ayanian, MD, MPP, and Deputy Editor Melinda B. Buntin, PhD, discuss the effects of these provisions on patients with Aaron S. Kesselheim, MD, JD, MPH, of Harvard Medical School and Brigham and Women's Hospital. Related Content: New Reforms to Prescription Drug Pricing in the US Estimating Rebates and Other Discounts Received by Medicare Part D Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018 Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017 Improving Prescription Drug Affordability Through Regulatory Action

President Biden has signed into law the Inflation Reduction Act containing important provisions related to prescription drug costs. JAMA Health Forum Editor John Z. Ayanian, MD, MPP, and Deputy Editor Melinda B. Buntin, PhD, discuss the effects of these provisions on patients with Aaron S. Kesselheim, MD, JD, MPH, of Harvard Medical School and Brigham and Women's Hospital. Related Content: New Reforms to Prescription Drug Pricing in the US Estimating Rebates and Other Discounts Received by Medicare Part D Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018 Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017 Improving Prescription Drug Affordability Through Regulatory Action

Interview with Aaron S. Kesselheim, MD, author of Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency Related Article(s): Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency

Interview with Aaron S. Kesselheim, MD, author of Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency Related Article(s): Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency

Interview with Aaron S. Kesselheim, MD, JD, MPH, author of Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials

What makes a drug’s price fair? In this episode of Ethics Talk, Dr. Aaron S. Kesselheim helped us talk through drug pricing: what makes it “fair,” how drugs are priced the way they are, and what some current legislative and market-based methods for curbing rising drug prices could look like.  

This episode features Aaron S. Kesselheim of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital discussing the 21st Century Cures Act. Read his commentary in CPT here. Listen and subscribe for free on iTunes and Google Play

This episode features Aaron S. Kesselheim of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital discussing the 21st Century Cures Act. Read his commentary in CPT here. Listen and subscribe for free on iTunes and Google Play